Company type | Aktiengesellschaft |
---|---|
SIX:
BION
[1] FWB: BBZA [2] Euronext: BIO.MI [3] | |
Industry | Investments |
Founded | 9 November 1993[4] |
Headquarters | Schaffhausen, Switzerland [5] |
Key people | Erich Hunziker ( Chairman) [6] |
Products | Investment in biotechnology companies |
CHF - 357 million (2022) [7] | |
Total assets | CHF 2.578 billion (2022) [7] |
Website | www.bbbiotech.ch |
BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and from 2000 to 2023 [8] on the Italian Borsa Italiana. [9] The company invests mainly in the United States and Western Europe [10] and is managed by Bellevue Asset Management, a division of Bellevue Group [11] which accounts for approximately 40% of the Group's assets under management. [12]
As a closed-end fund, with its principal activity of specialised investments in companies operating in biotech sector, [13] [14] BB Biotech is the oldest-established [12] and largest entity of its kind. [11] [15]
BB Biotech's investment strategy covers a long-term time horizon and targets biotechnology firms with either already established products in the marketplace [16] or promising drug candidates in advanced development stages. [17]
Aiming exclusively at human therapeutic companies, the company rules out med-tech, diagnostics and other similar activities [12] and further concentrates on firms developing therapeutic products [13] involving cell, gene and particularly RNA-based technologies. [12]
In contrast to other biotech specialists or hedge funds, Biotech as a long-only investor, does not need to rely on financial instruments to reduce individual stock or market risk. [12]
Primary geographic focus lies on small-to-mid-cap biotech companies headquartered in Western Europe [18] or the United States market [19] as a domicile for the majority of the world’s biotechnology companies, [20] or those listed on Nasdaq. [12]
While benchmarked against the Nasdaq Biotech index (in CHF), [21] [22] the company uses a bottom-up approach [17] based on the fundamental analysis. [12] Its portfolio comprises around 35 companies [14] and includes holdings in Ionis Pharmaceuticals, Moderna, Neurocrine Biosciences, Argenx, Incyte, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Arvinas, Fate Therapeutics, Agios Pharmaceuticals and Halozyme Therapeutics. [23]
Over the decade leading to 2020, it consistently met its own aim to deliver 15% of annual growth in capital [12] including a 5% dividend per year. [11]
BB Biotech AG mainly invests in the fields of oncology, cardiovascular diseases, metabolic diseases, infectious diseases and autoimmune diseases. [14]
The six core investments in the BB Biotech portfolio as of June 30, 2023 included Ionis Pharmaceuticals (13.3%), Argenx (11.7%), Vertex (10.4%), Neurocrine Biosciences (8.5%), Intra-Cellular Therapies (6.9%) and Moderna (6.2%). [24]
Company figures are as follows: [25] [26]
(figures in millions CHF) | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|---|
Profit/(Loss) | (356) [27] | (405) | 691 [7] [28] | 677 | (471) | 687 | (802) | 653 |
Net asset value | 2'686 | 3'283 | 3'888 [28] | 3'393 | 2'885 | 3'539 | 3'003 | 3'978 |
Market capitalization | 3'058 | 4’274 | 4108 [29] [28] | 3'670 | 3'235 | 3'576 | 3'053 | 3'463 |
Company type | Aktiengesellschaft |
---|---|
SIX:
BION
[1] FWB: BBZA [2] Euronext: BIO.MI [3] | |
Industry | Investments |
Founded | 9 November 1993[4] |
Headquarters | Schaffhausen, Switzerland [5] |
Key people | Erich Hunziker ( Chairman) [6] |
Products | Investment in biotechnology companies |
CHF - 357 million (2022) [7] | |
Total assets | CHF 2.578 billion (2022) [7] |
Website | www.bbbiotech.ch |
BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and from 2000 to 2023 [8] on the Italian Borsa Italiana. [9] The company invests mainly in the United States and Western Europe [10] and is managed by Bellevue Asset Management, a division of Bellevue Group [11] which accounts for approximately 40% of the Group's assets under management. [12]
As a closed-end fund, with its principal activity of specialised investments in companies operating in biotech sector, [13] [14] BB Biotech is the oldest-established [12] and largest entity of its kind. [11] [15]
BB Biotech's investment strategy covers a long-term time horizon and targets biotechnology firms with either already established products in the marketplace [16] or promising drug candidates in advanced development stages. [17]
Aiming exclusively at human therapeutic companies, the company rules out med-tech, diagnostics and other similar activities [12] and further concentrates on firms developing therapeutic products [13] involving cell, gene and particularly RNA-based technologies. [12]
In contrast to other biotech specialists or hedge funds, Biotech as a long-only investor, does not need to rely on financial instruments to reduce individual stock or market risk. [12]
Primary geographic focus lies on small-to-mid-cap biotech companies headquartered in Western Europe [18] or the United States market [19] as a domicile for the majority of the world’s biotechnology companies, [20] or those listed on Nasdaq. [12]
While benchmarked against the Nasdaq Biotech index (in CHF), [21] [22] the company uses a bottom-up approach [17] based on the fundamental analysis. [12] Its portfolio comprises around 35 companies [14] and includes holdings in Ionis Pharmaceuticals, Moderna, Neurocrine Biosciences, Argenx, Incyte, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Arvinas, Fate Therapeutics, Agios Pharmaceuticals and Halozyme Therapeutics. [23]
Over the decade leading to 2020, it consistently met its own aim to deliver 15% of annual growth in capital [12] including a 5% dividend per year. [11]
BB Biotech AG mainly invests in the fields of oncology, cardiovascular diseases, metabolic diseases, infectious diseases and autoimmune diseases. [14]
The six core investments in the BB Biotech portfolio as of June 30, 2023 included Ionis Pharmaceuticals (13.3%), Argenx (11.7%), Vertex (10.4%), Neurocrine Biosciences (8.5%), Intra-Cellular Therapies (6.9%) and Moderna (6.2%). [24]
Company figures are as follows: [25] [26]
(figures in millions CHF) | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|---|
Profit/(Loss) | (356) [27] | (405) | 691 [7] [28] | 677 | (471) | 687 | (802) | 653 |
Net asset value | 2'686 | 3'283 | 3'888 [28] | 3'393 | 2'885 | 3'539 | 3'003 | 3'978 |
Market capitalization | 3'058 | 4’274 | 4108 [29] [28] | 3'670 | 3'235 | 3'576 | 3'053 | 3'463 |